Drug Trial Radar · NCT06953063
A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects
Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
250
Actual
Start
May 15, 2025
Primary completion
Dec 15, 2025
Study completion Dec 15, 2025
Sponsor
- Lead sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.Industry
- Sponsor type
- Industry
- First posted
- May 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of DA-302168S tablets in overweight and obese adults.
Conditions
- Overweight and Obesity
Interventions
DA-302168SDrug
A small molecule GLP-1R agonist tablet, orally administration, once daily,16weeks.
Placebo of DA-302168SDrug
Matching placebo tablet will be provided
Primary outcomes
What the sponsor says the trial is designed to measure.
- percentage change in body weightTime frame: From baseline (week1) to week16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.